Found 83 articles
VILYA, Inc., a biotechnology company creating a new class of medicines that precisely target disease biology, announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.
Sanguine Biosciences Opens New Apheresis Donor Center to Support Cell & Gene Therapy and Translational Research Initiatives
Sanguine Biosciences, a leader in connecting patients with biomedical researchers to accelerate precision medicine R&D, announced its opening of a blood donor center in Los Angeles, California.
OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open-source software tools for biology and drug discovery
CytoDyn Inc. announced that it has filed a supplemental Statement of Claim and formally requested a hearing date in its litigation proceeding against Amarex Clinical Research LLC, the Company’s former Contract Research Organization.
CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that Dr. Cyrus Arman, the Company’s President, has taken a medical leave of absence.
CytoDyn Inc. announced that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Hansen, our newly appointed Head of Research and Basic Science, will host an investment community webcast to provide a Company update on Tuesday, April 11, 2023.
CytoDyn Inc. announced today that it will host a virtual R&D Update on Wednesday, December 7, 2022, beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company") today announced that it has voluntarily withdrawn its pending Biologics License Application (BLA) for leronlimab as a combination therapy in persons living with HIV with resistance to highly active antiretroviral therapy (HAART) in the HIV multi-drug resistant population (HIV-MDR).
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced additional changes in its Board of Directors (the “Board”).
Selecta Biosciences, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022.
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab
$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV.
Arzeda, Cyrus Biotechnology and Outpace Bio, are teaming up to use machine learning and optimize protein folding and design efforts.
Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022.
Selecta Biosciences, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
Vir Biotechnology, Inc. announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Data Challenge, sponsored by the Biomedical Advanced Research and Development Authority and the U.S. Department of Health and Human Services.
Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.
Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Selecta Biosciences, Inc. reported financial results for the quarter and full year ended December 31, 2021 and provided a business update.
Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection
Cyrus Biotechnology, Inc. today announced that its pre-clinical stage COVID therapeutic lead molecule, ACE2.v2.4 strongly binds the spike protein of SARS-CoV-2 variant of concern (VOC) omicron.